Jonah Sacha, PhD
Consultant
Jonah Sacha is an innovative infectious disease researcher with 20 years of experience in the field of infectious disease and immunology. With a track record in developing novel therapeutic modalities and prophylactic vaccines in humans and nonhuman primates (NHPs). His group has made discoveries that have informed human clinical trials and pioneered new NHP models of human disease, including the first macaque models of HBV infection and fully MHC-matched allogeneic stem cell transplantation.
Jonah is also a recognized expert in cellular immunology and described the first evidence of retrovirus-specific MHC-E-restricted CD8+ T cells. He joined OHSU in 2011 as an Assistant Professor after earning his Ph.D. in Medical Microbiology & Immunology at the University of Wisconsin-Madison. In 2023, he was appointed Chief of the Division of Pathobiology and Immunology. Jonah’s research program has been continuously funded by the NIH for over a decade. He holds nine awarded patents, serves as a member of the scientific advisory board for a publicly traded biotechnology company, and co-founded a biotechnology company developing therapeutics for infectious diseases.
Jonah is also a recognized expert in cellular immunology and described the first evidence of retrovirus-specific MHC-E-restricted CD8+ T cells. He joined OHSU in 2011 as an Assistant Professor after earning his Ph.D. in Medical Microbiology & Immunology at the University of Wisconsin-Madison. In 2023, he was appointed Chief of the Division of Pathobiology and Immunology. Jonah’s research program has been continuously funded by the NIH for over a decade. He holds nine awarded patents, serves as a member of the scientific advisory board for a publicly traded biotechnology company, and co-founded a biotechnology company developing therapeutics for infectious diseases.